Rasna Therapeutics, Inc. Closes Private Placement of $2 Million

Dec 27, 2016, RASP OTC Disclosure & News Service Rasna Therapeutics, Inc. (OTCQB:RASP), a development stage biotechnology company focused on the development of cancer drugs, today announced that it has closed a private placement to accredited investors of an aggregate 3,366,667 shares of common stock at $0.60 per share for gross proceeds of $2.02 million. The Company intends to use the proceeds for clinical development and working capital. About Rasna Therapeutics, Inc. Rasna Therapeutics, Inc. is a development stage
http://bit.ly/2iB2art